Arthritis Care &Research, Volume 77, Issue 10, Page 1229-1239, October 2025.Objective The objective of this study was to determine a core set of measures for youth with juvenile spondyloarthritis and axial disease (axJSpA), using the juvenile arthritis working group Outcome Measures in Rheumatology framework. Methods This was a prospective multicenter study of youth with axJSpA.
Timothy G. Brandon +8 more
wiley +1 more source
Serum chitotriosidase and neopterin levels in patients with ankylosing spondylitis
Therapeutic Advances in Musculoskeletal Disease, 2019 Background: The aim of this study was to assess the serum chitotriosidase (ChT) and neopterin levels in patients with ankylosing spondylitis (AS) and to evaluate whether serum ChT and neopterin levels are related to disease activity.
Ferdi Yavuz +3 more
doaj +1 more source
A Single Nucleotide Polymorphism in the Il17ra Promoter Is Associated with Functional Severity of Ankylosing Spondylitis [PDF]
, 2016 The aim of this study was to identify new genetic variants associated with the severity of ankylosing spondylitis (AS). We sequenced the exome of eight patients diagnosed with AS, selected on the basis of the severity of their clinical parameters.
Blanco García, Francisco Javier +13 more
core +6 more sources
JAK Inhibitors for Treatment of SAPHO Syndrome: A Systematic Review of 72 Cases
ACR Open Rheumatology, Volume 7, Issue 10, October 2025.Objective Synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome usually involves bones, joints, and skin. Due to a lack of known pathogenesis and clinical trials, there is no standard treatment of SAPHO syndrome. Because none of the current treatments have a high efficacy and the risk of relapse is high, new treatment options for ...
Patrick Fazeli +9 more
wiley +1 more source
Ankilozan Spondilit Hastalarında Yaşam Kalitesini ve Fonksiyonel Durumu Hangi Faktörler Etkiler?
Ankara Medical Journal, 2017 Giriş: Bu çalışma, Ankilozan spondilit (AS) hastalarında fonksiyonel durumu ve yaşam kalitesini etkileyen olası faktörleri belirlemek amacıyla yapıldı.Materyal ve Metot: Çalışmaya AS'li toplam 88 adet gönüllü Türk hasta dahil edildi.
Gülcan Gürer +4 more
doaj +1 more source
Increasing smoking intensity is associated with increased disease activity in axial spondyloarthritis. [PDF]
, 2016 A history of ever-smoking appears to be associated with a more severe disease phenotype in axial spondyloarthritis (axSpA). However, evidence is sparse for the effect of increased smoking exposure on disease outcomes or whether smoking reduction or ...
Challoner, B +4 more
core +1 more source
Immunity, Inflammation and Disease, Volume 13, Issue 10, October 2025.ABSTRACT Background Ankylosing spondylitis (AS) is a chronic autoimmune inflammatory disorder predominantly involving the axial skeleton. Understanding the cytokine and chemokine signatures in AS is crucial for elucidating disease mechanisms and identifying potential diagnostic biomarkers.
Huan Li +10 more
wiley +1 more source
Study protocol: Comparison of the effect of treatment with Nonsteroidal anti- inflammatory drugs added to anti-tumour necrosis factor a therapy versus anti- tumour necrosis factor a therapy alone on progression of Structural damage in the spine over two years in patients with ankyLosing spondylitis (CONSUL) – an open-label randomized controlled multicenter trial [PDF]
, 2017 Introduction There is some evidence that non-steroidal anti-inflammatory drugs (NSAIDs), in particular celecoxib, might possess not only a symptomatic efficacy but also disease-modifying properties in ankylosing spondylitis (AS), retarding the ...
Listing, Joachim +5 more
core +1 more source
POS0023 PERFORMANCE OF BASDAI VS. ASDAS IN EVALUATING AXIAL INVOLVEMENT IN PATIENTS WITH PSA TREATED WITH GUSELKUMAB: POOLED ANALYSIS OF TWO PHASE 3 STUDIES [PDF]
, 2023 Xenofon Baraliakos +8 more
openalex +1 more source
The Journal of Dermatology, Volume 52, Issue 10, Page 1527-1535, October 2025.ABSTRACT Psoriatic arthritis (PsA) is a chronic inflammatory disease, with prevalence among psoriasis patients ranging from 6% to 42% across populations. Although targeted therapies such as adalimumab (ADA), secukinumab (SEC), and upadacitinib (UPA) have demonstrated efficacy in randomized controlled trials, real‐world head‐to‐head comparisons remain ...
Yiyi Wang +11 more
wiley +1 more source